ArticleCureus2026
Venovenous Extracorporeal Membrane Oxygenation (VV-ECMO) Support in Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma With Pulmonary Involvement at Presentation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma is a rare and aggressive peripheral T-cell lymphoma typically diagnosed at advanced stages. Although venovenous extracorporeal membrane oxygenation (VV-ECMO) has been associated with poor outcomes in patients with active hematological malignancies, emerging evidence points to a potential benefit for carefully selected patients with severe acute respiratory failure due to cancer. We describe the clinical case of a 19-year-old male who initially presented with pleuritic chest pain and fever. Following a four-day hospitalization, he was discharged home with a diagnosis of acute pericarditis. Because of worsening symptoms with acute respiratory failure and newly developed lymphadenopathies, he was readmitted a few days later and diagnosed with nosocomial pneumonia. Despite treatment with broad-spectrum antibiotics, his condition worsened, necessitating mechanical ventilation and VV-ECMO to manage refractory hypoxemia. Subsequent investigation revealed the diagnosis of ALK-positive anaplastic large cell lymphoma with pulmonary involvement. Treatment with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisolone (CHOEP) chemotherapy led to significant clinical improvement, allowing successful VV-ECMO weaning. However, the disease relapsed shortly after with a comparable severity of respiratory failure, leading to a second VV-ECMO run combined with urgent BRESHAP (brentuximab vedotin, etoposide, methylprednisolone (Solu-Medrol), high-dose cytarabine (Ara-C), and cisplatin) chemotherapy. This strategy resulted in another successful VV-ECMO weaning. Although complete remission was achieved, stem cell transplantation was delayed due to pulmonary sequelae, and the patient declined further treatment. A second relapse occurred, and the patient died 12 months after diagnosis. This case report explores the potential utility of VV-ECMO as a bridge to recovery in carefully selected patients with treatable hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.